Target Price | $5.00 |
Price | $1.05 |
Potential |
376.19%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a Repare Therapeutics Inc price target 2026.
The average Repare Therapeutics Inc target price is $5.00.
This is
376.19%
register free of charge
|
|
A rating was issued by 4 analysts: 2 Analysts recommend Repare Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Repare Therapeutics Inc stock has an average upside potential 2026 of
376.19%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 53.48 | 5.05 |
4.60% | 90.56% | |
EBITDA Margin | -166.96% | -1,666.75% |
24.33% | 898.30% | |
Net Margin | -158.98% | -1,767.74% |
14.25% | 1,011.96% |
4 Analysts have issued a sales forecast Repare Therapeutics Inc 2025 . The average Repare Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Repare Therapeutics Inc 2025 . The average Repare Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Repare Therapeutics Inc 2025 . The average Repare Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.00 | -2.10 |
10.31% | 5.00% | |
P/E | negative | |
EV/Sales | negative |
1 Analysts have issued a Repare Therapeutics Inc forecast for earnings per share. The average Repare Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Repare Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
LifeSci Capital |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
Stifel |
Locked
➜
Locked
|
Locked | Dec 13 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 24 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 23 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 04 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
Locked
LifeSci Capital:
Locked
➜
Locked
|
Dec 13 2024 |
Locked
Stifel:
Locked
➜
Locked
|
Dec 13 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 08 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 24 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 23 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 04 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.